Results 151 to 160 of about 27,503 (257)

A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor. [PDF]

Cureus
Fukata M, Omura T, Maeda K, Mori T, Kato H, Kuzuya M.   +5 more
europepmc   +1 more source

The influence of dipeptidyl peptidase-4 inhibitor on the progression of type B intramural hematoma. [PDF]

Front Cardiovasc Med, 2022
Chen Q, Jiang D, Shan Z.
europepmc   +1 more source

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10318-10329, November 2026.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert, Ines Belalem, Corinne Vigouroux, Hippolyte Dupuis, Marie Christine Vantyghem, Mathilde Simonson, Estelle Nobecourt, Héléna Mosbah, Sophie Beliard, Stéphanie Jellimann, Sonja Janmaat, Camille Vatier, Sophie Lamothe   +12 more
wiley   +1 more source

Association of Dipeptidyl Peptidase-4 Inhibitor Use with COVID-19 Mortality in Diabetic Patients: A Nationwide Cohort Study in Korea. [PDF]

J Clin Med
Park JW, Kwak MK, Park S, Heo NH, Lee EY.   +4 more
europepmc   +1 more source

Quality of Diabetes Care Among Older Adults in Germany—Results of the Study on Health of Older People 2022/2023 Compared With Previous National Health Surveys

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10018-10027, November 2026.
ABSTRACT Aims The study aims (1) to evaluate the quality of diabetes care considering guideline‐recommended medical therapies, cardiometabolic factors, and self‐management of health behaviours among older adults with diabetes in Germany, and (2) to examine time trends.
Yong Du, Giselle Sarganas, Beate Gaertner, Maike Buchmann, Judith Fuchs, Hannelore Neuhauser, Christin Heidemann   +6 more
wiley   +1 more source

Evaluation of dipeptidyl peptidase-4 inhibitor-associated gastrointestinal symptoms using the prescription claims database. [PDF]

Sci Rep
Funabashi A, Ito H, Maeda M, Hasegawa Y, Tsukioka R, Onda M.   +5 more
europepmc   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9941-9954, November 2026.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

Inflammatory Bowel Disease in a Patient Returning from Colombia: Association with Dipeptidyl Peptidase 4 Inhibitor? [PDF]

Case Rep Gastroenterol
Bayoumy AB, Masclee GMC, de Boer NKH, Neefjes-Borst A, Stenvers DJ.   +4 more
europepmc   +1 more source

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10210-10217, November 2026.
ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder, Leah Shepherd, Hans Kristian Raket, Jerry R. Greenfield, Richard O. Day, Jialing Lin, Juliana de Oliveira Costa, Sophie Stocker, Carol A. Pollock, Brendon Neuen, Min Jun, Jane Ludington, Sallie‐Anne Pearson, Michael O. Falster   +13 more
wiley   +1 more source

Pharmacokinetics and Pharmacodynamics of Prusogliptin (DBPR108), a Once-Daily Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes. [PDF]

Clin Pharmacokinet
Liu W, Yang K, Lin Y, Lu C, Liu J, Zhou H, Wang J, Zhang T, Yao L, Qi H, Zhang X, Jia R, Li X, Jing S.   +13 more
europepmc   +1 more source